Anti–Factor Xa Activity of Fixed-Dose Fondaparinux in Low-Body-Weight Patients With Acute Coronary Syndrome

• المؤلفون الرئيسيون: Wanwarang Wongcharoen, Nualnit Tantisirivit, Lalita Norasetthada, Siriluck Gunaparn, Arintaya Phrommintikul
• التنسيق: دورية
• منشور في: 2020
• الموضوعات: Medicine
• الوصول للمادة أونلاين: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85085603716&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/70748

© The Author(s) 2020. Background: Fixed-dose 2.5 mg of fondaparinux subcutaneous injection once daily has been recommended in treatment of non-ST-segment elevation acute coronary syndrome (NSTE-ACS) irrespective of body weight (BW). However, data on anti–factor Xa (anti-FXa) activity of fondaparinux...